223 related articles for article (PubMed ID: 27937095)
1. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.
Knight KR; Chen L; Freyer D; Aplenc R; Bancroft M; Bliss B; Dang H; Gillmeister B; Hendershot E; Kraemer DF; Lindenfeld L; Meza J; Neuwelt EA; Pollock BH; Sung L
J Clin Oncol; 2017 Feb; 35(4):440-445. PubMed ID: 27937095
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
Landier W; Knight K; Wong FL; Lee J; Thomas O; Kim H; Kreissman SG; Schmidt ML; Chen L; London WB; Gurney JG; Bhatia S
J Clin Oncol; 2014 Feb; 32(6):527-34. PubMed ID: 24419114
[TBL] [Abstract][Full Text] [Related]
3. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
Clemens E; Brooks B; de Vries ACH; van Grotel M; van den Heuvel-Eibrink MM; Carleton B
PLoS One; 2019; 14(2):e0210646. PubMed ID: 30763334
[TBL] [Abstract][Full Text] [Related]
6. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
[TBL] [Abstract][Full Text] [Related]
7. Clinically accurate assessment and grading of ototoxicity.
Chang KW
Laryngoscope; 2011 Dec; 121(12):2649-57. PubMed ID: 22109766
[TBL] [Abstract][Full Text] [Related]
8. Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW; Chinosornvatana N
J Clin Oncol; 2010 Apr; 28(10):1788-95. PubMed ID: 20194861
[TBL] [Abstract][Full Text] [Related]
9. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
10. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
Colevas AD; Lira RR; Colevas EA; Lavori PW; Chan C; Shultz DB; Chang KW
Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
[TBL] [Abstract][Full Text] [Related]
11. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
[TBL] [Abstract][Full Text] [Related]
13. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
14. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
16. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
17. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052
[TBL] [Abstract][Full Text] [Related]
18. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
19. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma.
Guillaume DJ; Knight K; Marquez C; Kraemer DF; Bardo DM; Neuwelt EA
J Neurosurg Pediatr; 2012 Apr; 9(4):421-7. PubMed ID: 22462709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]